Comparison of hospitalized COVID-19 and influenza patients requiring supplemental oxygen in a cohort study: clinical impact and resource consumption.

Inmaculada López Montesinos\(^a\), Itziar Arrieta-Aldea\(^a\), Aitor Dicastillo\(^b\), Flavio Zuccarino\(^c\), Luisa Sorli\(^a\), Roberto Guerri-Fernández\(^a\), Isabel Arnau-Barrés\(^d\), Maria Milagro Montero\(^a\), Ana Siverio-Parès\(^a\), Xavier Durán\(^a\), Maria del Mar Arenas\(^a\), Ariadna Brasé Arnau\(^a\), Esperanza Cañas-Ruano\(^a\), Silvia Castañeda\(^a\), Ignacio Domingo Kamber\(^a\), Joan Gómez-Junyent\(^a\), Iván Pelegrín\(^a\), Francisca Sánchez Martínez\(^a\), Elena Sendra\(^a\), Lucía Suaya Leiro\(^a\), Judit Villar-García\(^a\), Xavier Nogués\(^a\), Santiago Grau\(^h\), Hernando Knobel\(^a\), Silvia Gomez-Zorrilla\(^a\),, Juan Pablo Horcajada\(^a\).

On behalf of COVID-MAR Group.*

a. Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra (UPF), Spanish Network for Research in Infectious Diseases (REIPI), Barcelona, 08003, Spain.

b. Universitat Pompeu Fabra (UPF), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

c. Department of Radiology, Hospital del Mar, Hospital Sant Joan de Deu, Barcelona, Spain.

d. Department of Geriatrics, Hospital del Mar, Barcelona, 08003, Spain.

e. Microbiology Service, Laboratori de Referència de Catalunya, El Prat de Llobregat (Barcelona), 08820, Spain.

f. Methodology and Biostatistics Support Unit, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, 08003, Spain.

g. Internal Medicine Service, Hospital del Mar, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra (UPF), Barcelona, 08003, Spain.

h. Pharmacy Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra (UPF), Barcelona 08003, Spain.

*Corresponding author information Silvia Gómez-Zorrilla, Infectious Diseases Service, Hospital del Mar (Barcelona, Spain). Passeig Marítim de la Barceloneta, 25-29, 08003, Barcelona, Spain. email: sgomezzorrilla@psmar.cat
Abstract

**Background:** To compare clinical characteristics, outcomes, and resource consumption of patients with COVID-19 and seasonal influenza requiring supplemental oxygen.

**Methods:** Retrospective cohort study conducted at a tertiary-care hospital. Patients admitted due to seasonal influenza between 2017 and 2019, or with COVID-19 between March and May 2020 requiring supplemental oxygen were compared. Primary outcome: 30-day mortality. Secondary outcomes: 90-day mortality and hospitalization costs. Attempted sample size to detect an 11% difference in mortality was 187 patients per group.

**Results:** COVID-19 cases were younger (median years, 67 (IQR 54-78) vs 76 (IQR 64-83); p<0.001) and more frequently overweight whereas influenza cases had more hypertension, immunosuppression, and chronic heart, respiratory and renal disease. Compared to influenza, COVID-19 cases had more pneumonia (98% vs 60%, <0.001), higher MEWS and CURB-65 scores and were more likely to show worse progression on the WHO ordinal scale (33% vs 4%; p<0.001). The 30-day mortality rate was higher for COVID-19 than for influenza: 15% vs 5% (p=0.001). The median age of non-surviving cases was 81 (IQR 74-88) and 77.5 (IQR 65-84) (p=0.385), respectively. COVID-19 was independently associated with 30-day (HR 4.6, 95%CI, 2-10.4) and 90-day (HR 5.2, 95%CI, 2.4-11.4) mortality. Sensitivity and subgroup analyses, including a subgroup considering only patients with pneumonia, did not show different trends. Regarding resource consumption, COVID-19 patients had longer hospital stays and higher critical care, pharmacy, and complementary test costs.

**Conclusions:** Although influenza patients were older and had more comorbidities, COVID-19 cases requiring supplemental oxygen on admission had worse clinical and economic outcomes.

**Key words:** COVID-19, flu, pandemic, mortality, resource consumption, hospital costs.
**Introduction**

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1], the coronavirus disease 2019 (COVID-19) has been compared to influenza virus. Both viruses are similar in symptoms, transmission routes, and risk groups.

Clinical presentation ranges from asymptomatic to critical cases, although most infections are not severe [2,3]. Among hospitalized patients however, the proportion of critical disease is higher, ranging from 3% to 20% for influenza, and from 14% to 50% for COVID-19 [4–8].

Both viruses can cause severe illness in otherwise healthy individuals, but elderly or comorbid patients are at highest risk of severe influenza illness [9]. In COVID-19, age plays a major role in outcome [10].

In terms of resource consumption, prior data show that seasonal influenza places a strain on the healthcare system [9]. However, the SARS-CoV-2 pandemic is a historic public health crisis, requiring unprecedented allocations of medical resources to ensure patient care and prevent health system collapse.

We hypothesized that adults with SARS-COV-2 requiring oxygen at admission have worse outcomes and consume more resources than those with influenza. Prior studies [4–8,11–22] have compared characteristics and/or outcomes of both diseases. To our knowledge, this is the first study to assess only patients requiring supplemental oxygen at admission. More relaxed admission criteria due to concerns about the novel SARS-COV-2 may have led to hospitalization of fewer sick people with COVID-19. Thus, considering only admitted patients requiring oxygen may provide a more objective selection criterion.

Furthermore, although some cohorts [4–8,16,18,20] have explored resource consumption, none have detailed the burden of disease on hospitalization costs.
This study aims to compare the clinical characteristics, mortality and resource consumption of patients hospitalized for COVID-19 or influenza requiring supplemental oxygen.

**Methods**

**Study design and participants**

A retrospective observational cohort study performed at the Hospital del Mar, a tertiary university hospital in Barcelona (Spain).

Patient selection was from the hospital database. Patients diagnosed with influenza or SARS-CoV-2 infection during the study period were retrospectively reviewed. Inclusion criteria were age >18-years, laboratory-confirmed influenza/SARS-CoV-2 infection, positive test within 48 hours of admission, hospitalization due to influenza/SARS-CoV-2 infection and need for supplemental oxygen at admission.

For the influenza cohort, patients hospitalized during the 2017–19 influenza outbreak periods (from January 1, 2017 through December 1, 2019) meeting the study criteria were included. For the COVID-19 cohort, patients admitted for COVID-19 from March 1, 2020 through May 1, 2020 (‘first wave’) were included. Patients were included consecutively, starting from the initial date of the study period until the required sample size was reached.

Patients were followed for 90 days from the date of the positive test, using the regional electronic healthcare records (integrating hospital, primary care, and long-term facilities). Patients whose mortality could not be assessed due to lack of records during the follow-up period were considered lost to follow-up and excluded. Hospital-acquired infections were excluded to avoid overestimating hospitalization costs and length of stay accounted for before the COVID-19 or influenza episode.
Ethics

The Clinical Research Ethical Committee of Parc Salut Mar approved this study (registration no. 2021/9892). Written informed consent was waived due to its observational and retrospective nature.

Outcomes

The primary endpoint was all-cause 30-day mortality. Secondary endpoints were 90-day mortality and hospitalization costs.

Definitions and data collection

Demographic, clinical, and epidemiological data were collected from electronic records. Influenza and pneumococcal vaccination status was ascertained through primary care records. Patients with no official vaccination record were considered “not vaccinated”. Severity of underlying diseases were assessed by Charlson comorbidity index [23]. Immunosuppression was defined as malignancy, untreated HIV and/or CD4 count <200 cells/µl, pregnancy, inflammatory and autoimmune disorders, transplant or other diseases under immunosuppressive agents, corticosteroid therapy, defined as 10 mg of oral prednisone or equivalent for a month, poorly controlled diabetes mellitus, defined as HbA1c>9% with target organ damage, and/or primary immune deficiency disease.

Also recorded were signs and symptoms at admission, time from symptom onset to hospital admission, laboratory test parameters, baseline chest X-ray findings, treatment received, need for intensive care unit (ICU) admission, and respiratory support. Chest X-rays were classified into 2 groups: those with new radiographic findings consistent with acute pneumonia (ground-glass, linear opacities, or consolidations), and those normal or showing non-acute findings.
(chronic changes associated with prior pneumopathy) or not attributable to viral infection (pulmonary edema).

Clinical severity was assessed at admission using Modified Early Warning Score (MEWS) [24], CURB-65 [25], and PaO2/FiO2 ratio. Acute respiratory distress syndrome (ARDS) was defined as PaO2/FiO2 ratio ≤300 [26]. When arterial blood gas data were not available, PaO2/FiO2 ratio was inferred from Spo2/Fio2 [27]. Status on the World Health Organization (WHO) ordinal clinical progression scale [28] at baseline and day 7 was also recorded.

Complications developing during hospitalization (pulmonary embolism, secondary infections, heart failure, atrial fibrillation, acute kidney injury) were recorded.

Variables studied for healthcare resource consumption included: length of stay, days in ICU, days of respiratory support, readmissions, and overall hospitalization, pharmaceutical, laboratory, imaging, and other diagnostic procedure costs.

**Statistical analysis**

Determination of the sample size (187 patients per group) to detect at least an 11% difference in mortality between groups was based on previous results [4]. Statistical power was set at 0.8, alpha error 0.05, and estimated loss to follow-up 0.3.

Continuous quantitative variables were presented as median and interquartile range (IQR), categorical variables as numbers and percentages. Categorical variables were compared by χ² test or Fisher’s exact test, and continuous variables by the Student’s t-test or Mann–Whitney U-test, as appropriate.

The Kaplan-Meier estimator estimated time-until-death. The log-rank test compared the risk of death between study groups. Receiver Operating Characteristic (ROC) curves were used to identify the optimal cutoff age for prediction of 30- and 90-day mortality, and Youden’s criterion to determine optimal cutoff points: the sample point maximizing the Youden Index (sensitivity+specificity–1).
Cox proportional hazards was used to perform multivariate survival analyses of 30- and 90-day mortality, with hazard ratios (HR) and 95% confidence intervals (CI). Variables with p value ≤.2 were included in the initial model, together with variables not statistically significant but clinically relevant. Corticosteroid therapy and pneumonia were considered clinically relevant and forced into models. Baseline MEWS score and PaO2/FiO2 ratio were included to adjust for severity. Complications during hospitalization were considered intermediate variables between exposure and death and were not included. Cox models were built using backward stepwise selection. Variance inflation factors were used to detect collinearity between variables in the models. The proportional hazards assumption was tested. Variables with > 25% missing values were not considered.

Sensitivity analyses were performed to investigate the impact of COVID-19 versus influenza on 30- and 90-day mortality in subgroups of interest (age <74 or ≥74-years; including only non-influenza vaccinated patients and those with pneumonia and/or bilateral involvement).

Economic impact was evaluated by median regression to deal with lack of normality of dependent variables (hospitalization costs). Results were expressed as difference of medians. Interpretation of coefficients, as in multiple linear regression, was based on differences of means.

All p-values were 2-tailed and statistical significance was <0.05. Statistical analyses were performed using STATA 15.1. STROBE guidelines were used to report the study (Supplementary Table S1).
Results

Overall, 614 COVID-19 patients and 411 influenza patients were admitted during the study period. Based on the attempted sample size, 187 patients were included per group (Figure 1).

Baseline characteristics and clinical presentation

Differences in baseline characteristics, clinical presentation, complementary tests, complications, and therapeutic management between groups are shown in table 1. The most frequent subtype viruses were influenza A H1N1 (65%) and B (26.74%).

COVID-19 patients were younger than those with influenza and had fewer underlying diseases. Overall, influenza cases had worse abnormal blood count values, excluding ferritin and hepatic enzyme levels. Pneumonia was seen more in COVID-19 than influenza patients (98% vs 59%; p<0.001). Among influenza cases with no pneumonia (n=77), 41 (53%) had radiological changes secondary to chronic pneumopathy and clinical signs of acute exacerbation, 19 (25%) pulmonary edema, and 17 (22%) had normal x-rays but wheezing and/or rales on examination. More than 86% of these 77 patients reported influenza systemic symptoms.

Severity assessment

COVID-19 patients presented higher MEWS and CURB-65 scores at baseline, but mild ARDS was more frequent in influenza cases (66% vs 50%; p=0.022). Evolution of patient status on the WHO ordinal scale during admission is shown in Figure 2.

Therapeutic management and complications

58% of patients received virus-targeting agents. Nearly all influenza cases (98%) received oseltamivir. COVID-19 patients were given lopinavir/ritonavir (17%) and remdesivir (1%). Overall, more than 90% of patients received concomitant antibiotic therapy. The most frequent
regimen in the COVID-19 group was ceftriaxone plus azithromycin (72%) versus amoxicillin/clavulanate (30%) and levofloxacin (21%) in influenza group.

Concomitant bacterial pneumonia at admission was more frequent in influenza than COVID-19 cases (n=39/43, 90.7% vs n=8/27, 29.6%, p<0.001). *Streptococcus pneumoniae* was the leading microorganism (26 and 4 episodes, respectively). Hospital-acquired pneumonia was more seen in COVID-19 (n=19/27, 70.4%) than influenza group (n=4/43, 9.3%) and *Pseudomonas aeruginosa* was the most frequent microorganism (n=8 and n=2 patients, respectively). Patients with COVID-19 were more likely to have hospital-acquired infections other than pneumonia (20% vs 3%, p<0.001) and to develop bacteremia (14% vs 4%, p=0.001).

**Clinical outcome: mortality**

30-day mortality was 15% (n=29/187) in COVID-19 and 5% (n=10/187) in influenza (HR 3.07, 95%CI, 1.5–6.31). Median age was 81 years (IQR 74-88) in COVID-19 and 77.5 years (IQR 65-84) in influenza (p=0.385). 70% of influenza deaths were caused by influenza A subtype H1N1.

90-day mortality was 19% (n=35/187) in COVID-19 and 6% (n=12/187) in influenza (HR 3.12, 95%CI, 1.62–6.02). Median age was 78 (IQR 72-87) in COVID-19, and 77.5 (IQR 64-84.5) in influenza (p=0.558). Influenza A subtype H1N1 (67%) and influenza B (25%) were the most common subtypes in non-surviving influenza patients.

There were no differences in mortality trends between the three periods of seasonal influenza studied.

Figure 3A shows Kaplan-Meier curves for 30-day mortality by infection group. Based on ROC curve analysis, the optimal cutoff age for predicting mortality was 74 years (Figure S1). When stratified by age, 30-day mortality was markedly higher in COVID-19 patients ≥74-years (HR
5.77, 95% CI, 2.48–13.47; p<0.001) (Figure 3B). In patients under 50-years, only one death, in the COVID-19 group, was observed.

Univariate and multivariate analyses of 30-day mortality are shown in Table 2. COVID-19 was an independent risk factor for 30-day mortality. Data of 90-day mortality are shown in supplementary material (Table S2 and Figure S2). Similarly, COVID-19 was also associated with higher 90-day mortality.

Subgroup and sensitivity analyses of the impact of COVID-19 versus influenza on 30- and 90-day mortality in subgroups of interest are shown in supplementary table S3. COVID-19 was also associated with higher 30- and 90-day mortality considering only patients with pneumonia (Table 3 and supplementary table S4, respectively) and non-vaccinated against influenza (supplementary table S5).

**Healthcare resource consumption and costs**

COVID-19 patients had longer hospital and ICU stays. Critical care costs for COVID-19 patients were almost twice those associated with influenza patients, with a median difference of 9,268 euros between groups (p<0.001) (Table 4). COVID-19 was independently associated with higher costs of critical care, pharmaceutical treatment, and complementary tests (supplementary Table S6 and S7).

**Discussion**

The present study details clinical characteristics, outcomes, and resource consumption of patients hospitalized for COVID-19 or influenza requiring supplemental oxygen on admission.

COVID-19 patients were younger and healthier than those with influenza, as previously reported [4,6,16–18,22], with consistent differences in rates of smoking, hypertension, pneumopathy, heart failure, and renal disease. Since many patients with pneumopathy were treated with
corticoid therapy, immunosuppression was especially high in the influenza group. COVID-19 individuals however tended to have higher BMIs [4].

Whereas COVID-19 cases had more general symptoms, dyspnea and ARDS were more seen in influenza patients at baseline. In contrast, COVID-19 cases were more likely to worse during admission. These findings describe the natural history of some COVID-19 cases, who develop respiratory deterioration during the inflammatory stage of the disease [29].

As previously reported, bacterial pulmonary coinfections were uncommon in COVID-19 at baseline [30], which contrasts with previous data from influenza epidemics [31]. Conversely, hospital-acquired infections were more frequent with COVID-19 due to longer hospital and ICU stays.

Concerning outcomes, mortality was three times higher for COVID-19 than influenza, which coincides with previous data [4–6,8,20]. Our data suggest that mortality was especially high among older patients (≥74-years) with COVID-19, which reinforces previous evidence [10] identifying age as a key factor in COVID-19 outcomes. Due to the limited number of observations for younger individuals, the burden of influenza and COVID-19 on younger cohorts warrants further investigation.

COVID-19 cases had more frequently pneumonia and bilateral involvement. Prior studies have shown that COVID-19 typically follows a peripheral bilateral pattern, with a predominance of ground-glass, linear opacities or consolidations depending on the stage of the disease [32]. Although bilateral pattern is frequent in influenza, prior series have also found lower rates of bilateral involvement [33].

Most non-surviving cases had pneumonia on chest X-ray. In our cohort, 40% of influenza cases baseline X-rays did not show viral pneumonia. Previous studies [34] show computed tomography (CT) scan is the “gold standard” for detection of pneumonia, since lung opacities
are visible on CT scan when X-rays are normal. In one study [35], the proportion of influenza pneumonia increased from 7% to 72% when CT scan was performed. It can be inferred that a pneumonia diagnosis may be missed using X-rays alone.

Moreover, in clinical practice, clinical and radiographic overlap may make it difficult to differentiate between viral pneumonia and acute exacerbations of chronic pulmonary disease or congestive heart failure [36,37].

To explore the impact of radiological findings on outcome, pneumonia was forced into multivariate models of mortality and subgroup analyses were performed. In all settings, COVID-19 outcomes were worse. Excess mortality may be due to increased intrinsic severity in COVID-19, and not only exacerbation of chronic conditions or presence of pneumonia.

None of the COVID-19 patients were immunized during the study period, which contrasts with 17% of vaccinated influenza patients. Subgroup analysis excluding vaccinated influenza patients did not show different trends.

Therapeutic management may also have affected outcomes. Almost the whole influenza cohort received oseltamivir, whereas remdesivir was administered in just 1% of COVID-19 cases. Furthermore, almost 40% of COVID-19 patients did not receive corticosteroids. While current evidence supports corticosteroid therapy in COVID-19 cases [38], its administration was controversial during the study period [39]. To explore the effect of treatment on outcome, corticosteroids and antiviral treatment were entered as covariates in multivariate analysis. Antiviral treatment was removed from the final model due to the lack of significant differences.

Since we included three seasonal influenza outbreaks (2017-2019), the differences in mortality are unlikely to be the result of an unusually mild influenza season. Of note, it was necessary to review almost three periods of seasonal influenza versus two months of COVID-19 to reach the attempted sample size, reflecting the huge influx of patients in our institution during the first
wave of the COVID-19 pandemic. It may be inferred that the sudden demand for hospital resources may have negatively affected care of COVID-19 cases.

Our findings on resource consumption show that patients with SARS-COV-2 more frequently received respiratory support, were almost three times more likely to be admitted to the ICU and had longer hospital and ICU stays. The costs of critical care, pharmaceutical treatment and complementary tests were also higher in the COVID-19 group. While previous studies [4–6,8,16,18] have found that COVID-19 patients consume more resources in terms of hospital stay and ICU bed occupancy, this is to our knowledge the first to detail those costs.

Our study has the limitations of a retrospective, single-center study. No genotyping studies were conducted due to the timing of study data collection, although it is highly likely that COVID-19 patients were affected by wild-type B.1. These results may not therefore reflect the current scenario, in which multiple SARS-CoV-2 variants are circulating globally. Likewise, the absence of vaccinated COVID-19 patients during the study period may not reflect the current profile of inpatients with COVID-19. Second, patients with COVID-19 and seasonal influenza cannot be compared directly because the cohorts come from different time periods. Third, many influenza cases did not present pneumonia on admission. Even though CT is considered the gold standard for detecting pneumonia, pulmonary X-ray findings could have been considered an additional inclusion criterion. Fourth, antiviral was used for the influenza group, for which studies have shown a decrease in mortality [40]. In contrast, for patients with COVID-19 there was no effective antiviral therapy. Fifth, during the first wave of the pandemic, SARS-CoV-2 detection was occasionally performed alone. Nevertheless, it is unlikely that influenza co-infections were missed in our study because of the study timing. Finally, considerable effort was made to fully adjust for a few covariates; nevertheless, the overall number of events was low, which limits the precision of some estimates, particularly for important subgroups. We did not include interesting laboratory parameters such as ferritin, d-dimer, or interleukin-6 in multivariable models because
of higher proportions of missing values, particularly in the influenza cohort. Several strengths of this study are highlighted. All information was reviewed by trained investigators, which contrasts with studies based on administrative or automated databases where the accuracy of data may not guarantee. Furthermore, the study explores the dimension of resource consumption, a keystone of pandemic management. Finally, we only included patients when infection was the reason for admission, providing an accurate estimation of the true impact of SARS-COV-2 and influenza on hospitalization costs.

In conclusion, COVID-19 was associated with worse clinical and economic outcomes than seasonal influenza in hospitalized patients requiring supplemental oxygen. COVID-19-related hospitalization seems to be more complex and expensive than influenza, either because of greater clinical severity, length of stay, ICU bed occupancy, need for respiratory equipment, or other special measures. Healthcare managers should take this into account to improve healthcare activity and prepare for possible future waves of COVID-19, especially in the current scenario, where the possibility of overlapping influenza and COVID-19 epidemics could mean increased complexity in patient management.

NOTES

Acknowledgements: We would like to thank Dr. Klaus Langohr (Statistics and Operation Research Department of Polytechnic University of Catalonia) as statistical advisor. We also thank Albert Anglés and Francesc Cots Reguant for providing the necessary economic data and Janet Dawson for English editing. Finally, we thank Dr M.L. Cos Esquius, Dr E. García Vives, Dr C. Gimenez Argente, Dr I. González Farias, Dr S. Modino Pérez, Dr I. Petit Salas, Dr A.S. Rial Villavecchia, Dr J. Rodríguez Morera, and Dr J. Soldado Folgado for their contribution to the COVID-MAR Group.

Funding: This study was carried out as part of our routine work.
Conflicts of interest: ILM reports Rio Hortega Grant Instituto Carlos III CM18/00047 from January 2018 to December 2020, unrelated to this work; and support by Pfizer and Angelini to attend meetings (no payment to author; registration to meetings only). IAA reports Rio Hortega Grant Instituto Carlos III, unrelated to this work. LS reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, Angelini, and Menarini. RGF reports grants or contracts unrelated to this work: FIS ISCIII PI19/00019; honoraria for lectures and presentations from Gilead inc, MSD, GSK; and participation on GC2010 DSMB Interim Safety Data Review. SC reports support by Pfizer, Angelini and MSD to attend meetings (no payments to author; registration to meetings only). JGJ reports support by Pfizer, Angelini and MSD to attend meetings (no payments to author; registration to meetings only). XN reports payment or honoraria for Amgen UCB lectures; Support for attending meetings and/or travel from Amgen, Lilly; and participation on a Data Safety Monitoring Board or Advisory Board for Amegrn, UCB. SGZ reports grants or contracts unrelated to this study: FIS ISCIII PI21/00509, Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). JPH reports honoraria for lectures from Pfizer, Angelini, Menarini, MSD; and participation on advisory boards for Menarini, MSD, GILEAD. All other authors, no conflict.
References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382:727–733. Available at: http://www.nejm.org/doi/10.1056/NEJMoa2001017.

2. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 2010; 28:4895–4902. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0264410X1000719X.

3. Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020; 52:583–589. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1074761320301205.

4. Piroth L, Cottenet J, Mariet A-S, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med 2021; 9:251–259. Available at: https://linkinghub.elsevier.com/retrieve/pii/S2213260020305270.

5. Ludwig M, Jacob J, Basedow F, Andersohn F, Walker J. Clinical outcomes and characteristics of patients hospitalized for Influenza or COVID-19 in Germany. Int J Infect Dis 2021; 103:316–322. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1201971220325200.

6. Xie Y, Bowe B, Maddukuri G, Al-Aly Z. Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. BMJ 2020; :m4677. Available at: https://www.bmj.com/lookup/doi/10.1136/bmj.m4677.

7. Nasir N, Khanum I, Habib K, et al. Comparison of clinical characteristics and outcomes between COVID-19 pneumonia and H1N1 influenza. Adv Respir Med 2021; 89:254–261.
8. Donnino MW, Moskowitz A, Thompson GS, et al. Comparison between Patients Hospitalized with Influenza and COVID-19 at a Tertiary Care Center. J Gen Intern Med 2021; 36:1689–1695. Available at: https://link.springer.com/10.1007/s11606-021-06647-2.

9. Lina B, Georges A, Burtseva E, et al. Complicated hospitalization due to influenza: results from the Global Hospital Influenza Network for the 2017–2018 season. BMC Infect Dis 2020; 20:465. Available at: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05167-4.

10. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020; 20:669–677. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1473309920302437.

11. Deng L-S, Yuan J, Ding L, et al. Comparison of patients hospitalized with COVID-19, H7N9 and H1N1. Infect Dis Poverty 2020; 9:163. Available at: https://idpjournal.biomedcentral.com/articles/10.1186/s40249-020-00781-5.

12. Qu J, Chang LK, Tang X, et al. Clinical characteristics of COVID-19 and its comparison with influenza pneumonia. Acta Clin Belg 2020; 75:348–356. Available at: https://www.tandfonline.com/doi/full/10.1080/17843286.2020.1798668.

13. Shen C, Tan M, Song X, et al. Comparative Analysis of Early-Stage Clinical Features Between COVID-19 and Influenza A H1N1 Virus Pneumonia. Front Public Heal 2020; 8. Available at: https://www.frontiersin.org/article/10.3389/fpubh.2020.00206/full.

14. Gjurašin B, Santini M, Krajinović V, et al. A retrospective comparison between influenza
and COVID-19-associated ARDS in a Croatian tertiary care center. Wien Klin Wochenschr 2021; 133:406–411. Available at: https://link.springer.com/10.1007/s00508-020-01759-x.

15. Zhang J, Ding D, Huang X, et al. Differentiation of COVID-19 from seasonal influenza: A multicenter comparative study. J Med Virol 2021; 93:1512–1519. Available at: https://onlinelibrary.wiley.com/doi/10.1002/jmv.26469.

16. Serpa Neto A, Burrell AJC, Bailey M, et al. Comparison of Critical Care Occupancy and Outcomes of Critically Ill Patients during the 2020 COVID-19 Winter Surge and 2009 H1N1 Influenza Pandemic in Australia. Ann Am Thorac Soc 2021; 18:1380–1389. Available at: https://www.atsjournals.org/doi/10.1513/AnnalsATS.202010-1311OC.

17. Burn E, You SC, Sena AG, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun 2020; 11:5009. Available at: https://www.nature.com/articles/s41467-020-18849-z.

18. Auvinen R, Nohynek H, Syrjänen R, et al. Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients – a prospective observational study. Infect Dis (Auckl) 2021; 53:111–121. Available at: https://www.tandfonline.com/doi/full/10.1080/23744235.2020.1840623.

19. Chen X, Wang Z, Bromfield SG, DeVries A, Pryor D, Willey V. Identification and Comparison of Patient Characteristics for Those Hospitalized with COVID-19 versus Influenza Using Machine Learning in a Commercially Insured US Population. Pragmatic Obs Res 2021; Volume 12:9–13. Available at: https://www.dovepress.com/identification-and-comparison-of-patient-characteristics-for-those-hos-peer-reviewed-fulltext-article-POR.
20. Cobb NL, Sathe NA, Duan KI, et al. Comparison of Clinical Features and Outcomes in Critically Ill Patients Hospitalized with COVID-19 versus Influenza. Ann Am Thorac Soc 2021; 18:632–640. Available at: https://www.atsjournals.org/doi/10.1513/AnnalsATS.202007-805OC.

21. Tang X, Du R-H, Wang R, et al. Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1. Chest 2020; 158:195–205. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0012369220305584.

22. Zayet S, Kadiane-Oussou NJ, Lepiller Q, et al. Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. Microbes Infect 2020; 22:481–488. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1286457920300940.

23. Charlson ME, Pompei P, Ales KL, MacKenzie RC. A New Method of Classifying Prognostic in Longitudinal Studies: Development. J Chronic Dis 1987; 40:373–383.

24. Subbe CP, Davies RG, Williams E, Rutherford P, Gemmell L. Effect of introducing the Modified Early Warning score on clinical outcomes, cardio-pulmonary arrests and intensive care utilisation in acute medical admissions*. Anaesthesia 2003; 58:797–802. Available at: http://doi.wiley.com/10.1046/j.1365-2044.2003.03258.x.

25. Lim WS. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377–382. Available at: https://thorax.bmj.com/lookup/doi/10.1136/thorax.58.5.377.

26. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818–824. Available at:
http://www.atsjournals.org/doi/abs/10.1164/ajrccm.149.3.7509706.

27. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the Sp o 2 /F io 2 Ratio and the Pa o 2 /F io 2 Ratio in Patients With Acute Lung Injury or ARDS. Chest 2007; 132:410–417. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0012369215374316.

28. Marshall JC, Murthy S, Diaz J, et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20:e192–e197. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1473309920304837.

29. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant 2020; 39:405–407. Available at: https://linkinghub.elsevier.com/retrieve/pii/S105324982031473X.

30. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis 2020; Available at: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa530/5828058.

31. Morris DE, Cleary DW, Clarke SC. Secondary Bacterial Infections Associated with Influenza Pandemics. Front Microbiol 2017; 8. Available at: http://journal.frontiersin.org/article/10.3389/fmicb.2017.01041/full.

32. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology 2020; 295:715–721.

33. Reyes S, Montull B, Martínez R, et al. Risk factors of A/H1N1 etiology in pneumonia and its impact on mortality. Respir Med 2011; 105:1404–1411.
34. Self WH, Courtney DM, McNaughton CD, Wunderink RG, Kline JA. High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia. Am J Emerg Med 2013; 31:401–405. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0735675712004639.

35. Schoen K, Horvat N, Guerreiro NFC, de Castro I, de Giassi KS. Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity. BMC Infect Dis 2019; 19:964. Available at: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-4592-0.

36. Black AD. Non-infectious mimics of community-acquired pneumonia. Pneumonia 2016; 8:2. Available at: http://pneumonia.biomedcentral.com/articles/10.1186/s41479-016-0002-1.

37. Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs Nonpneumonic Acute Exacerbations of COPD. Chest 2002; 122:1264–1270. Available at: https://linkinghub.elsevier.com/retrieve/pii/S001236921537793X.

38. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384:693–704. Available at: http://www.nejm.org/doi/10.1056/NEJMoa2021436.

39. Li H, Chen C, Hu F, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia 2020; 34:1503–1511. Available at: http://www.nature.com/articles/s41375-020-0848-3.

40. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395–404. Available at: https://linkinghub.elsevier.com/retrieve/pii/S2213260014700414.
Table 1. Baseline characteristics, clinical presentation, laboratory and radiological findings, infection severity, complications and therapeutic management of COVID-19 and influenza Inpatients requiring supplemental oxygen.

| Variable                          | 2017-2019 Influenza (n=187) | COVID-19 (n=187) | p-value |
|-----------------------------------|------------------------------|-----------------|---------|
| Demographic information           |                              |                 |         |
| Male sex                          | 102 (54.5)                   | 91 (48.7)       | 0.255   |
| Age (years), m (IQR)              | 76 (64-83)                   | 67 (54-78)      | <0.001  |
| Distribution                      |                              |                 |         |
| 18 – 30 years                     | 1 (0.5)                      | 2 (1.1)         | 0.562   |
| 31 – 40 years                     | 4 (2.1)                      | 6 (3.2)         | 0.521   |
| 41 – 50 years                     | 7 (3.7)                      | 27 (14.4)       | <0.001  |
| 51 – 60 years                     | 20 (10.7)                    | 29 (15.5)       | 0.168   |
| 61 – 70 years                     | 38 (20.3)                    | 41 (21.9)       | 0.704   |
| 71 – 80 years                     | 58 (31)                      | 47 (25.1)       | 0.206   |
| 81 – 90 years                     | 56 (29.9)                    | 28 (15)         | <0.001  |
| ≥ 91 years                        | 3 (1.6)                      | 7 (3.7)         | 0.200   |
| Ethnic group                      |                              |                 |         |
| Arab                              | 2 (1.1)                      | 11 (5.9)        | 0.010   |
| Asian                             | 0 (0)                        | 9 (4.9)         | 0.002   |
| Latin American                    | 5 (2.7)                      | 13 (7)          | 0.050   |
| White                             | 178 (95.2)                   | 150 (81.1)      | <0.001  |
| Other                             | 2 (1.1)                      | 4 (2.2)         | 0.410   |
| Underlying condition              |                              |                 |         |
| Charlson comorbidity index, m (IQR) | 2 (1-4)                    | 1 (0-2)         | <0.001  |
| Dependent for activities of daily living | 48 (25.7)                | 29 (15.5)      | 0.015   |
| Current smoker                    | 55 (29.4)                    | 13 (7)          | <0.001  |
| Hypertension                      | 134 (71.7)                   | 108 (57.8)      | 0.005   |
| Dyslipidemia                      | 85 (45.5)                    | 72 (38.5)       | 0.173   |
| Diabetes                          | 58 (31)                      | 43 (23)         | 0.081   |
| COPD                              | 80 (42.8)                    | 24 (12.8)       | <0.001  |
| Asthma                            | 19 (10.2)                    | 6 (3.2)         | 0.007   |
| Chronic heart disease             | 86 (42.2)                    | 28 (15)         | <0.001  |
| Chronic neurologic disorder       | 18 (9.6)                     | 30 (16)         | 0.064   |
| Chronic kidney disease            | 49 (26.2)                    | 7 (3.7)         | <0.001  |
| Liver disease                     | 15 (8)                       | 21 (11.2)       | 0.293   |
| Immunosuppression                 | 119 (63.6)                   | 24 (12.8)       | <0.001  |
| Malignancy                        | 17 (9.1)                     | 11 (5.9)        | 0.238   |
| Inflammatory and autoimmune disorders | 22 (11.8)                | 7 (3.7)         | 0.004   |
| Long-term oral corticosteroids    | 53 (28.3)                    | 3 (1.6)         | <0.001  |
| Other*                            | 27 (14.4)                    | 3 (1.6)         | <0.001  |
|                              | No (IQR)       | No. of patients with indication |
|------------------------------|----------------|-------------------------------|
| **HIV chronic infection**    | 7 (3.7)        | 5 (2.7)                       |
| **BMI, m (IQR)**             | 26.3 (23.6-31.6)| 28.4 (25.1-32.5)              |
| **Overweight, BMI ≥ 25 kg/m²**| 102 (60.7)     | 136 (76)                      |
| **Vaccination status**       |                |                               |
| Influenza vaccination        | 30 (17.2)      | (30/174)                      |
| Pneumococcal vaccination     | 45 (26.9)      | (45/167)                      |
| **Clinical presentation**    |                |                               |
| Days from illness onset to admission, m (IQR) | 4 (2.7) | 8 (5.1-11) | <0.001 |
| Fever                        | 111 (59.4)     | 156 (83.4)                    |
| Malaise                      | 123 (65.8)     | 142 (75.9)                    |
| Headache                     | 5 (2.7)        | 35 (18.7)                     |
| Altered level of consciousness | 16 (8.6)       | 23 (12.3)                     |
| Gastrointestinal disorders   | 12 (6.4)       | 61 (32.6)                     |
| Anosmia and/or dysgeusia     | 0 (0)          | 29 (15.5)                     |
| Upper respiratory tract symptoms | 40 (21.4)     | 52 (27.8)                     |
| Cough                        | 154 (82.4)     | 152 (81.3)                    |
| Dyspnea                      | 156 (83.4)     | 115 (61.5)                    |
| **Laboratory parameter, m (IQR)** |          |                               |
| Hemoglobin, g/l              | 12.6 (11.2-14.3)| 13.4 (12.2-14.5)             |
| Leukocyte count, x10⁹/L      | 9.3 (4.1-10.9) | 6.6 (5.1-9.9)                 |
| Neutrophil count, x10⁹/L     | 7.5 (5.1-10.9) | 5.2 (3.5-8.5)                 |
| Lymphocyte count, x10⁹/L     | 0.9 (0.6-10.9) | 0.9 (0.7-1.3)                 |
| Platelet count, x10⁹/L       | 194 (148-263)  | 203 (156-278)                 |
| Urea, mg/dl                  | 51 (34.8-80)   | 35 (28-50)                    |
| Creatinine, mg/dl            | 1.1 (0.8-1.6)  | 0.9 (0.7-1.1)                 |
| Serum albumin, g/dl          | 3.4 (2.9-3.7)  | 3.5 (3.2-3.8)                 |
| Total bilirubin, mg/dl       | 0.4 (0.3-0.7)  | 0.4 (0.3-0.6)                 |
| Alanine aminotransferase, U/L| 19 (13-32)     | 25 (16.8-43.2)                |
| Aspartate aminotransferase, U/L| 25 (18-36) | 35 (24-51)                     |
| Lactate dehydrogenase, U/L   | 333 (251-428)  | 308 (249-425)                 |
| Creatine kinase, U/L         | 210 (100-477)  | 90 (53-218)                   |
| C-reactive protein, mg/dl    | 9.1 (3.5-23.2) | 9.6 (4.2-20.9)                |
| Procalcitonin, ng/ml         | 0.6 (0.2-3.4)  | 0.1 (0.09-0.4)                |
| Ferritin, ng/ml              | 435 (154-1148) | 670 (374-1320)                |
| **Interleukin 6, pg/ml** | - | 55.2 (19-107) | - |
|-------------------------|---|----------------|---|
|                         | (0/187) | (153/187) | - |
| **D-dimer, mcg/L**      | - | 840 (490-1580) | - |
|                         | (0/187) | (179/187) | - |
| **Troponin T, ng/L**    | 42.4 (22.6-108.1) | 14 (13.2-25.2) | <0.001 |
|                         | (29/187) | (169/187) | - |
| **NT-proBNP, pg/ml**    | 3960 (1258-9891) | 192 (95-623) | <0.001 |
|                         | (78/187) | (77/187) | - |

**Radiological findings on chest X-ray at admission**

(No./No. of patients with pneumonia)

| **Pneumonia** | 110 (58.8) | 183 (97.9) | <0.001 |
|---------------|------------|------------|--------|
| Ground-glass opacities/consolidation | 66 (60) | 72 (39.3) | 0.001 |
| Linear opacities | 45 (40.9) | 146 (79.8) | <0.001 |
| Bilateral involvement | 53 (48.2) | 160 (87.4) | <0.001 |
| Pleural effusion | 12 (10.9) | 2 (1.1) | 0.001 |

**Severity assessment**

| **Baseline MEWS, m (IQR)** | 2 (0-3) | 3 (2-4) | <0.001 |
|-----------------------------|---------|---------|--------|
| **Baseline CURB-65, m (IQR)** | 1 (1-1) | 1 (1-2) | <0.001 |
| **Baseline PaO2/FiO2 ratio, m (IQR)** | 267 (211-330) | 304 (214-372) | 0.238 |
| **ARDS** | 123 (65.8) | 86 (46) | <0.001 |
| Moderate-severe ARDS | 42 (22.5) | 43 (23) | 0.902 |

**Baseline WHO ordinal scale**

| **Admitted to hospital, receiving supplemental oxygen** | 140 (74.9) | 151 (80.7) | 0.171 |
|--------------------------------------------------------|------------|------------|--------|
| **Admitted to hospital, receiving NIV or HFNC** | 39 (20.9) | 27 (14.4) | 0.104 |
| **Admitted to hospital, receiving MIV** | 8 (4.3) | 9 (4.8) | 0.804 |

**Day 7 WHO ordinal scale**

| **Not admitted to hospital** | 35 (18.7) | 20 (10.7) | 0.029 |
|-------------------------------|------------|------------|--------|
| **Admitted to hospital, without supplemental oxygen** | 42 (22.5) | 27 (14.4) | 0.046 |
| **Admitted to hospital, receiving supplemental oxygen** | 91 (48.7) | 64 (34.2) | 0.005 |
| **Admitted to hospital, receiving NIV or HFNC** | 10 (5.3) | 18 (9.6) | 0.116 |
| **Admitted to hospital, receiving MIV, or death** | 9 (4.8) | 58 (31) | <0.001 |

**Complications during admission**

| **Bacterial pneumonia** | 43 (23) | 27 (14.4) | 0.034 |
|-------------------------|---------|------------|--------|
| **Non-respiratory bacterial infection** | 5 (2.7) | 38 (20.3) | <0.001 |
| **Pulmonary embolism** | - | 17 (9.1) | 0.048 |
| **Heart failure** | 56 (29.9) | 20 (10.7) | <0.001 |
| **Atrial fibrillation** | 24 (12.8) | 13 (7) | 0.057 |
| **Acute kidney injury** | 24 (12.8) | 41 (21.9) | 0.020 |

**Therapeutic management**

| **Antibiotic** | 169 (90.4) | 180 (96.3) | 0.023 |
|----------------|------------|------------|--------|
| **Antiviral** | 184 (98.4) | 34 (18.2) | <0.001 |
| **Corticosteroids** | 180 (80.2) | 115 (61.5) | <0.001 |
| **Interleukin 6 inhibitors** | - | 48 (25.7) | <0.001 |
| Pronation | 5 (2.7) | 73 (39) | <0.001 |

Data are presented as nos. and % or as medians (m) with interquartile ranges (IQR). Abbreviations: COVID-19 (coronavirus disease 2019), COPD (chronic obstructive pulmonary disease), HIV (human immunodeficiency virus), BMI (body mass index), N-terminal pro-B-type natriuretic peptide (NT-proBNP), Modified Early Warning Score (MEWS), non-invasive ventilation (NIV), high-flow nasal cannula (HFNC), invasive mechanical ventilation (IMV), Intensive care unit (ICU), acute respiratory distress syndrome (ARDS).

*Other: Diabetes mellitus 9, primary immunosuppression 5, immunosuppressive agents 4, renal transplant 5, untreated HIV and/or CD4 count < 200 cells/µl4, immunosuppressive agents 4 in influenza cases. Renal transplant 2 and pregnancy 1 in COVID-19 cases.
Table 2. Cox regression analysis of associations between main variables and mortality at day 30.

| Variable                                      | Crude analysis | Adjusted analysis |
|-----------------------------------------------|----------------|------------------|
|                                              | HR (95%CI)     | p value          | HR (95%CI)     | p value          |
| COVID-19                                      | 3.07 (1.5-6.31) | 0.002            | 4.56 (2.01-10.43) | <0.001           |
| Demographic information                       |                |                  |                |                  |
| Male sex                                      | 1.69 (0.88-3.25) | 0.117            | 3.02 (1.44-3.36) | 0.004            |
| Age (per unit)                                | 1.07 (1.04-1.04) | <0.001           | 1.09 (1.06-1.13) | <0.001           |
| Underlying condition                          |                |                  |                |                  |
| Charlson comorbidity index (per unit)         | 1.7 (1.01-1.36) | 0.038            | 1.19 (0.99-1.43) | 0.060            |
| Dependent for activities of daily living      | 3.34 (1.87-5.95) | <0.001           |                |                  |
| Current smoker                                | 0.51 (0.18-1.41) | 0.190            |                |                  |
| Hypertension                                  | 1.86 (0.89-3.95) | 0.098            |                |                  |
| Dyslipidemia                                  | 1.47 (0.83-2.75) | 0.231            |                |                  |
| Diabetes                                      | 1.07 (0.53-2.14) | 0.650            |                |                  |
| COPD                                          | 1.46 (0.76-2.81) | 0.258            |                |                  |
| Chronic heart disease                         | 1.28 (0.65-2.46) | 0.463            |                |                  |
| Chronic neurologic disorder                   | 4.01 (2.06-7.8) | <0.001           |                |                  |
| Chronic kidney disease                        | 0.82 (0.32-2.09) | 0.677            |                |                  |
| Malignancy                                    | 1.4 (0.5-3.95) | 0.521            |                |                  |
| Immunosuppression                             | 0.46 (0.22-0.97) | 0.043            |                |                  |
| HIV/AIDS                                      | 0.66 (0.35-1.26) | 0.207            |                |                  |
| BMI (per unit)                                | 1.01 (0.9-1.01) | 0.270            |                |                  |
| Severity assessment                           |                |                  |                |                  |
| Baseline MEWS (per unit)                      | 1.41 (1.21-1.64) | <0.001           | 1.59 (1.31-1.94) | <0.001           |
| Baseline CURB-65 (per unit)                   | 2.24 (1.7-2.93) | <0.001           |                |                  |
| Baseline PaO2/FiO2 ratio (per unit)            | 1 (0.99-1)      | 0.046            | 1 (0.99-1.01)  | 0.086            |
| Baseline WHO ordinal scale                    |                |                  |                |                  |
| Admitted to hospital, receiving supplemental oxygen | Reference |                |                |                  |
| Admitted to hospital, receiving NIV or HFNC   | 0.53 (0.19-1.5) | 0.233            |                |                  |
| Admitted to hospital, receiving MIV           | 1.59 (0.49-5.21) | 0.440            |                |                  |
| Day 7 WHO ordinal scale                       |                |                  |                |                  |
| Admitted to hospital, receiving supplemental oxygen | Reference |                |                |                  |
| Admitted to hospital, receiving NIV or HFNC   | 3.58 (1.3-9.84) | 0.014            |                |                  |
| Admitted to hospital, receiving MIV           | 2.96 (1.23-7.1) | 0.015            |                |                  |
| Worsening on WHO ordinal scale (per unit)     | 7.64 (4.03-14.47) | <0.001           |                |                  |
| Radiological findings in chest X-ray          |                |                  |                |                  |
| Pneumonia                                     | 5.38 (1.3-22.34) | 0.020            | 1.82 (0.38-8.64) | 0.451            |
| Ground-glass opacities/consolidation          | 1.67 (0.89-3.12) | 0.111            |                |                  |
| Linear opacities                              | 1.97 (1.01-3.83) | 0.046            |                |                  |
| Bilateral involvement                         | 1.18 (0.56-2.5) | 0.666            |                |                  |
| Pleural effusion                              | 1.41 (0.34-5.86) | 0.634            |                |                  |
| Complications during admission                |                |                  |                |                  |
| Bacterial pneumonia                           | 0.77 (0.32-1.83) | 0.549            |                |                  |
Non-respiratory bacterial infection & 4.1 (2.11-7.99) & <0.001 \\
Pulmonary embolism & 0.4 (0.06-2.92) & 0.365 \\
Heart failure & 1.35 (0.66-2.77) & 0.412 \\
Atrial fibrillation & 2.87 (1.36-6.04) & 0.006 \\
Acute kidney injury & 4.42 (2.35-8.3) & <0.001 \\

| Therapeutic management                  |          |          |
|----------------------------------------|----------|----------|
| Antibiotic                             | 2.76 (0.38-20.1) | 0.317 |
| Antiviral                              | 0.42 (0.22-0.79) | 0.008 |
| Corticosteroids                        | 0.83 (0.45-1.53) | 0.548 | 0.34 (0.16-0.73) | 0.006 |
| Interleukin 6 inhibitors               | 0.93 (0.38-2.3) | 0.883 |
| Pronation                              | 0.96 (0.44-2.08) | 0.912 |

Abbreviations: COVID-19 (coronavirus disease 2019), COPD (chronic obstructive pulmonary disease), HIV/AIDS (human immunodeficiency virus/acquired immune deficiency syndrome), BMI (body mass index), Modified Early Warning Score (MEWS), non-invasive ventilation (NIV), high-flow nasal cannula (HFNC), invasive mechanical ventilation (IMV), intensive care unit (ICU).

Variables explored in the initial multivariate model were group (COVID-19 or influenza), sex, age, Charlson comorbidity index, current smoker, hypertension, dyslipidemia, immunosuppression, BMI, baseline PaO2/FiO2, baseline MEWS, pneumonia, bilateral involvement, antiviral and corticosteroids therapy.

The adjusted model showed a statistical power of 97.25%.
Table 3. Cox regression analysis of associations between main variables and mortality at day 30 in the subgroup of patients with pneumonia at baseline.

| Variable                                      | Crude analysis | Adjusted analysis |
|-----------------------------------------------|----------------|-------------------|
| Variable                                      | HR (95%CI)     | p value           | HR (95%CI)     | p value           |
| COVID-19                                      | 2.39 (1.05-5.02) | 0.038             | 5.18 (2.08-12.9) | <0.001            |
| Demographic information                       |                |                   |                |                   |
| Male sex                                      | 1.62 (0.84-3.15) | 0.155             | 2.96 (1.38-6.36) | 0.005             |
| Age (per unit)                                | 1.08 (1.04-1.11) | <0.001            | 1.1 (1.06-1.14)  | <0.001            |
| Underlying condition                          |                |                   |                |                   |
| Charlson comorbidity index (per unit)         | 1.21 (1.05-1.39) | 0.007             | 1.22 (1.02-1.47) | 0.005             |
| Dependent for activities of daily living      | 4.78 (2.5-9.1)  | <0.001            |                |                   |
| Current smoker                                | 0.56 (0.17-1.82) | 0.336             |                |                   |
| Hypertension                                  | 2.32 (1.06-5.08) | 0.035             |                |                   |
| Dyslipidemia                                  | 1.56 (0.82-2.98) | 0.178             |                |                   |
| Diabetes                                      | 1.25 (0.62-2.53) | 0.537             |                |                   |
| COPD                                          | 1.86 (0.95-3.66) | 0.071             |                |                   |
| Chronic heart disease                         | 1.4 (0.71-2.76)  | 0.324             |                |                   |
| Chronic neurologic disorder                   | 3.93 (1.97-7.83) | <0.001            |                |                   |
| Chronic kidney disease                        | 1.14 (0.46-2.94) | 0.780             |                |                   |
| Malignancy                                    | 1.49 (0.53-4.2)  | 0.453             |                |                   |
| Immunosuppression                             | 0.62 (0.28-1.65) | 0.225             |                |                   |
| HIV/AIDS                                      | 0.78 (0.11-5.72) | 0.810             |                |                   |
| BMI (per unit)                                | 1.01 (0.99-1.01) | 0.360             |                |                   |
| Severity assessment                           |                |                   |                |                   |
| MEWS (per unit)                               | 1.35 (1.14-1.59) | <0.001            | 1.52 (1.24-1.88) | <0.001            |
| CURB-65 (per unit)                            | 2.06 (1.56-2.87) | <0.001            |                |                   |
| Baseline PaO2/FiO2 ratio (per unit)           | 1 (0.99-1.01)   | 0.108             | 1 (0.99-1.01)   | 0.061             |
| Baseline WHO ordinal scale                    |                |                   |                |                   |
| Admitted to hospital, receiving supplemental  | Reference       |                   | Reference       |                   |
| oxygen                                       |                |                   |                |                   |
| Admitted to hospital, receiving NIV or HFNC   | 0.37 (0.11-1.21) | 0.099             |                |                   |
| Admitted to hospital, receiving MIV           | 1.32 (0.4-4.32)  | 0.645             |                |                   |
| Day 7 WHO ordinal scale                       |                |                   |                |                   |
| Admitted to hospital, receiving supplemental  | Reference       |                   | Reference       |                   |
| oxygen                                       |                |                   |                |                   |
| Admitted to hospital, receiving NIV or HFNC   | 2.61 (0.87-7.79) | 0.086             |                |                   |
| Admitted to hospital, receiving MIV           | 2.5 (1.02-6.15)  | 0.046             |                |                   |
| Worsening on WHO ordinal scale (per unit)     | 6.68 (3.43-12.98) | <0.001            |                |                   |
| ICU admission                                 | 1 (0.5-1.99)   | 0.997             |                |                   |
| Radiological findings in chest X-ray          |                |                   |                |                   |
| Ground-glass opacities/consolidation          | 1.2 (0.63-2.28)  | 0.586             |                |                   |
| Linear opacities                              | 1.29 (0.64-2.61) | 0.481             |                |                   |
| Bilateral involvement                         | 1.18 (0.56-2.5)  | 0.666             | 0.83 (0.36-1.92) | 0.663             |
| Pleural effusion                              | 1.24 (0.3-5.17)  | 0.765             |                |                   |
| Complications                                 |                |                   |                |                   |
| Bacterial pneumonia                           | 0.74 (0.31-1.77) | 0.498             |                |                   |
| Condition                              | Odds Ratio (95% CI) | p-value |
|----------------------------------------|---------------------|---------|
| Non-respiratory bacterial infection    | 3.65 (1.86-7.18)    | <0.001  |
| Pulmonary embolism                     | 0.37 (0.05-2.74)    | 0.332   |
| Heart failure                          | 1.54 (0.75-3.19)    | 0.240   |
| Atrial fibrillation                    | 2.1 (0.96-4.59)     | 0.064   |
| Acute kidney injury                    | 4.3 (2.26-8.2)      | <0.001  |

**Therapeutic management**

| Therapy                  | Odds Ratio (95% CI) | p-value |
|--------------------------|---------------------|---------|
| Antibiotic               | 1.22 (0.17-8.93)    | 0.842   |
| Antiviral                | 0.55 (0.28-1.08)    | 0.082   |
| Corticosteroids          | 0.61 (0.32-1.18)    | 0.146   |
| Interleukin 6 inhibitors | 0.75 (0.3-1.86)     | 0.532   |
| Pronation                | 0.79 (0.36-1.72)    | 0.548   |

**Abbreviations:** COVID-19 (coronavirus disease 2019), COPD (chronic obstructive pulmonary disease), HIV/AIDS (human immunodeficiency virus/acquired immune deficiency syndrome), BMI (body mass index), non-invasive ventilation (NIV), high-flow nasal cannula (HFNC), invasive mechanical ventilation (IMV), intensive care unit (ICU).

Variables explored in the initial multivariate model: group (COVID-19 or influenza), sex, age, Charlson comorbidity index, current smoker, hypertension, dyslipidemia, BMI, baseline PaO2/FiO2, baseline MEWS, bilateral involvement, antiviral and corticosteroid therapy. Bilateral involvement was forced into the model.

The adjusted model showed a statistical power of 98.2%.
Table 4. Univariate analysis of healthcare resource consumption and economic impact for Influenza and COVID-19 patients in the overall cohort and in the pneumonia subgroup.

|                   | 2017-2019 Influenza | COVID-19 | p-value |
|-------------------|---------------------|----------|---------|
| **Overall cohort**|                     |          |         |
| **Healthcare resource consumption** | |          |         |
| Length of stay, days | 11 (8-17) | 14 (8-26) | <0.001  |
| Length of stay in ICU, days | 10 (7-15) | 17 (9-27) | 0.005   |
| Days of NIV or HFNC | 5 (2-8) | 4 (2-6) | 0.577   |
| Days of IMV | 11 (5-15) | 15 (10-22) | 0.276   |
| Readmissions, 90 days, n (%) | 53 (28.3) | 5 (2.7) | <0.001  |
| **Costs, €** | |          |         |
| Overall cost of hospitalization | 5996 (4049-10955) | 6448 (3690-15435) | 0.238   |
| Cost of critical care | 12082 (6594-22284) | 21350 (11309-42558) | <0.001  |
| Cost of pharmacy | 132 (53-256) | 156 (42-1934) | 0.022   |
| Cost of laboratory tests, imaging | 275 (155-571) | 925 (628-1560) | <0.001  |
| plus other complementary tests | | | |
| **Pneumonia subgroup** | |          |         |
| **Healthcare resource consumption** | |          |         |
| Length of stay, days | 11.5 (8-17) | 15 (8-26) | <0.001  |
| Length of stay in ICU, days | 10 (7-15) | 17 (9-27) | 0.010   |
| Days of NIV or HFNC | 5 (2.5-8) | 4 (2-6.25) | 0.532   |
| Days of IMV | 11 (6-14) | 15 (10-22) | 0.013   |
| Readmissions, 90 days, n (%) | 28 (25.5) | 5 (2.7) | <0.001  |
| **Costs, €** | |          |         |
| Overall cost of hospitalization | 4370 (7494-12504) | 6621 (3723-16164) | 0.008   |
| Cost of critical care | 13258 (8694-23149) | 21350 (11309-42558) | 0.001   |
| Cost of pharmacy | 146 (64-273) | 166 (43-1982) | <0.001  |
| Cost of laboratory tests, imaging | 360 (215-921) | 930 (637-1569) | <0.001  |
| plus other complementary tests | | | |

Data are presented as means (m) and interquartile range (IQR) unless otherwise specified. Cost values are shown in euros (€). Abbreviations: COVID-19 (coronavirus disease 2019), non-invasive ventilation (NIV), high-flow nasal cannula (HFNC), invasive mechanical ventilation (IMV), intensive care unit (ICU).
Figure Legends:

Figure 1. Flowchart of patients included in the study.

Abbreviations: COVID-19 (coronavirus disease 2019).

Figure 2. Progression of influenza and COVID-19 patients on WHO ordinal scale during admission. Status on the WHO ordinal scale at baseline (A) and at day 7 (B).

Abbreviations: COVID-19 (coronavirus disease 2019), non-invasive ventilation (NIV), high flow nasal cannula (HFNC), invasive mechanical ventilation (IMV).

Figure 3. Cumulative Kaplan-Meier estimates of (A) probability of overall survival at day 30 in influenza and SARS-CoV-2 virus groups and (B) stratified by age ≥ 74 years.

Abbreviations: COVID-19 (coronavirus disease 2019).
Figure 1
150x84 mm (x DPI)
Figure 2
102x149 mm (x DPI)
Figure 3
102x149 mm (x DPI)